Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

Scott Solomon, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Katelin Jackson, Xu Zhang, H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2025) 146 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2025-4194

Published: 2025

Journal Articles

Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation

Dawn Speckhart, Krishi Patel, Jennifer Guevara, Joyce Izundu, Xu Zhang, Scott Solomon, H Kent Holland, Asad Bashey, Joseph Maakaron, Lizamarie Bachier-Rodriguez, Melhem Solh

Blood (2025) 146 (Supplement 1): 2839.

https://doi.org/10.1182/blood-2025-2839

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center

Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier-Rodriguez, Joseph Maakaron, Scott Solomon, Melhem Solh

Blood (2025) 146 (Supplement 1): 6211.

https://doi.org/10.1182/blood-2025-6211

Published: 2025

Journal Articles

Outcomes for allogeneic transplant in myelofibrosis remain suboptimal in the modern era despite increased use of post-transplant cyclophosphamide and pre-transplant JAK inhibition.

Scott Solomon, Joseph Maakaron, Lizamarie Bachier-Rodriguez, Melhem Solh, Katelin Jackson, Xu Zhang, H. Kent Holland, Asad Bashey

Blood (2025) 146 (Supplement 1): 7830.

https://doi.org/10.1182/blood-2025-7830

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Journal Articles

Incidence, predictors and consequences of poor graft function after post-transplant cyclophosphamide (PTCy)-based allogeneic transplantation

Lizamarie Bachier Rodriguez, Asad Bashey, H. Kent Holland, Melhem Solh, Joseph Maakaron, Katelin Jackson, Xu Zhang, Scott Solomon

Blood (2025) 146 (Supplement 1): 7709.

https://doi.org/10.1182/blood-2025-7709

Published: 2025

Journal Articles

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Blood (2024) 144 (Supplement 1): 7367.

https://doi.org/10.1182/blood-2024-207521

Published: 2024

Journal Articles

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Scott R. Solomon, Melissa Sanacore, Lizamarie Bachier Rodriguez, Latasha McCoy, Caitlin Guzowski, Katelin C Jackson, Xu Zhang, H. Kent Holland, Lawrence E Morris, Melhem M. Solh, Asad Bashey

Blood (2024) 144 (Supplement 1): 3528.

https://doi.org/10.1182/blood-2024-199618

Published: 2024

Journal Articles

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Asad Bashey, Xu Zhang, H. Kent Holland, Lawrence E Morris, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2024-209117

Published: 2024

Journal Articles

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Steven Baker, Asad Bashey, Lizamarie Bachier-Rodriguez, Lawrence E Morris, H Kent Holland, Justin Laporte, Scott R. Solomon, Melissa Sanacore, Melhem Solh

Blood (2024) 144 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2024-210395

Published: 2024

Journal Articles

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Justin Laporte, Katelin Jackson, Xu Zhang, Asad Bashey, Lawrence E Morris, Lizamarie Bachier Rodriguez, Melhem M. Solh, Scott R. Solomon, H. Kent Holland

Blood (2024) 144 (Supplement 1): 7333.

https://doi.org/10.1182/blood-2024-200207

Published: 2024

Journal Articles

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

Scott R. Solomon, Melissa Sanacore, Asad Bashey, Katelin C Jackson, Lizamarie Bachier Rodriguez, Lawrence E Morris, H. Kent Holland, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2024-200103

Published: 2024

Journal Articles

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

Asad Bashey, Xu Zhang, Lawrence E Morris, H. Kent Holland, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2024-209199

Published: 2024

Journal Articles

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Scott R. Solomon, Christina Roark, Michael T Aubrey, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Brian Freed, Asad Bashey

Blood (2024) 144 (Supplement 1): 4948.

https://doi.org/10.1182/blood-2024-210627

Published: 2024

Journal Articles

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Asad Bashey, Michael T Aubrey, Brian Freed, Christina Roark, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4913.

https://doi.org/10.1182/blood-2024-210329

Published: 2024

Journal Articles

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Melhem M. Solh, Asad Bashey, Lawrence E Morris, Lizamarie Bachier-Rodriguez, H. Kent Holland, Xu Zhang, Rajveer Singh, Katelin Jackson, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2024-208659

Published: 2024

Journal Articles

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2023-186117

Published: 2023

Journal Articles

Impact of Allograft T-Cell (CD3) Dose on Outcomes When CD34 Cell Dose Is Capped: Analysis of 811 Consecutive Allogeneic PBSC Transplants from a Single Center

Asad Bashey, Xu Zhang, Lawrence Morris, Kent Holland, Lizamarie Bachier-Rodriguez, Melhem M. Solh, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2023-180383

Published: 2023

Journal Articles

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Lan Lei, Asad Bashey, Scott R. Solomon, Lawrence Morris, H Kent Holland, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Lizamarie Bachier Rodriguez

Blood (2023) 142 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2023-190663

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center

Outcomes for allogeneic transplant in myelofibrosis remain suboptimal in the modern era despite increased use of post-transplant cyclophosphamide and pre-transplant JAK inhibition.

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Incidence, predictors and consequences of poor graft function after post-transplant cyclophosphamide (PTCy)-based allogeneic transplantation

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Impact of Allograft T-Cell (CD3) Dose on Outcomes When CD34 Cell Dose Is Capped: Analysis of 811 Consecutive Allogeneic PBSC Transplants from a Single Center

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only